Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors

© 2019 by the authors.

Detalles Bibliográficos
Autores: Nieto, Celia, Centa, Ariana, Rodríguez-Rodríguez, Jesús A., Pandiella, Atanasio, Martín del Valle, Eva María
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/203664
Acceso en línea:http://hdl.handle.net/10261/203664
Access Level:acceso abierto
Palabra clave:Targeted nanoparticles
Paclitaxel
Trastuzumab
HER2-specificity
Sodium alginate
Piperazine
id ES_ee737f6af81ea9dbfbf2bbaaa158fe9f
oai_identifier_str oai:digital.csic.es:10261/203664
network_acronym_str ES
network_name_str España
repository_id_str
spelling Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumorsNieto, CeliaCenta, ArianaRodríguez-Rodríguez, Jesús A.Pandiella, AtanasioMartín del Valle, Eva MaríaTargeted nanoparticlesPaclitaxelTrastuzumabHER2-specificitySodium alginatePiperazine© 2019 by the authors.Paclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2). Methods: Alginate and piperazine nanoparticles were synthetized and conjugated with paclitaxel:β-cyclodextrins complexes and trastuzumab. Conjugated nanoparticles (300 nm) were characterized and their internalization in HER2-overexpressing tumor cells was analyzed by immunofluorescence. Its specific antitumor activity was studied in vitro using human cell lines with different levels of HER2-expression. Results: In comparison with free paclitaxel:β-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis. Conclusions: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells.This work was supported by a UE ERC Starting Grant (MYCAP. Development of a technology to produce microcapsules, based on the formation of drops from viscous non-Newtonians liquids sprayed through fan-jet nozzles, to use in cancer therapy), by the Spanish Ministry of Economy and Competitiveness (BFU2012-39151, BFU2015-71371R, CTQ2016-78988-R, PI15/00684, and FEDER), the CRIS Cancer Foundation and the Scientific Foundation of the Spanish Association Against Cancer (AECC). CN is recipient of a predoctoral contract from the Junta de Castilla y León, co-funded by the European Social Foundation (EDU/602/2016) and AC was supported by a doctoral fellowship from Coordination for the Improvement of Higher Education Personnel (CAPES) from the Ministry of Education of Brazil.Multidisciplinary Digital Publishing InstituteMinisterio de Economía y Competitividad (España)Fundación CRIS contra el CáncerAsociación Española Contra el CáncerJunta de Castilla y LeónEuropean CommissionCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brasil)Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2020202020192020info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/203664reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE##PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2015-71371-Rinfo:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/CTQ2016-78988-Rhttp://dx.doi.org/10.3390/nano9070948Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/2036642026-05-22T06:33:51Z
dc.title.none.fl_str_mv Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
title Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
spellingShingle Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
Nieto, Celia
Targeted nanoparticles
Paclitaxel
Trastuzumab
HER2-specificity
Sodium alginate
Piperazine
title_short Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
title_full Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
title_fullStr Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
title_full_unstemmed Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
title_sort Paclitaxel-trastuzumab mixed nanovehicle to target HER2-overexpressing tumors
dc.creator.none.fl_str_mv Nieto, Celia
Centa, Ariana
Rodríguez-Rodríguez, Jesús A.
Pandiella, Atanasio
Martín del Valle, Eva María
author Nieto, Celia
author_facet Nieto, Celia
Centa, Ariana
Rodríguez-Rodríguez, Jesús A.
Pandiella, Atanasio
Martín del Valle, Eva María
author_role author
author2 Centa, Ariana
Rodríguez-Rodríguez, Jesús A.
Pandiella, Atanasio
Martín del Valle, Eva María
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Economía y Competitividad (España)
Fundación CRIS contra el Cáncer
Asociación Española Contra el Cáncer
Junta de Castilla y León
European Commission
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Brasil)
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Targeted nanoparticles
Paclitaxel
Trastuzumab
HER2-specificity
Sodium alginate
Piperazine
topic Targeted nanoparticles
Paclitaxel
Trastuzumab
HER2-specificity
Sodium alginate
Piperazine
description © 2019 by the authors.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/203664
url http://hdl.handle.net/10261/203664
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
#PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/BFU2015-71371-R
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/CTQ2016-78988-R
http://dx.doi.org/10.3390/nano9070948
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423672087805952
score 15,811543

Similares en LA Referencia